Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron blocks serotonin type‑3 (5‑HT3) receptors located on vagal afferent nerves in the gut and in the brain’s chemoreceptor trigger zone. By inhibiting these receptors, it stops serotonin‑driven signaling that would otherwise activate the vomiting centre, providing protection against both acute and delayed emetic episodes.

The prescribed dose of Palonosetron Fresenius Kabi is determined by the treating physician based on the chemotherapy regimen, patient weight and clinical guidelines. The prescriber selects the appropriate amount and timing, and the medication is administered intravenously shortly before the emetogenic trigger.

Palonosetron should be used in pregnancy or while breastfeeding only if the potential benefit justifies any potential risk to the fetus or infant. Limited data are available, so clinicians assess each case individually and consider alternative antiemetics when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Palonosetron has a longer half‑life and higher receptor affinity than first‑generation 5‑HT3 antagonists such as ondansetron, allowing single‑dose coverage of both acute and delayed nausea. It is often preferred when prolonged antiemetic protection is desired, though choice depends on patient factors and treatment protocols.

The product should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. Do not freeze or expose the solution to extreme temperatures.

Palonosetron Fresenius Kabi is supplied as a sterile solution for intravenous injection. It is typically given as a single infusion over a few minutes, administered shortly before the start of chemotherapy, radiotherapy or anesthesia, according to the prescribing clinician’s instructions.

Serious adverse events include allergic reactions such as anaphylaxis, QT‑interval prolongation leading to cardiac arrhythmias, and rare cases of serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for signs of these conditions during and after administration.

Palonosetron is contraindicated in individuals with known hypersensitivity to palonosetron or any other 5‑HT3 antagonist. Caution is also advised for patients with significant cardiac conduction abnormalities, uncontrolled electrolyte disturbances, or those taking multiple QT‑prolonging medications.